Rising Prevalence and Spending on Cancer will Escalate the US Peptide Therapeutics Market

The US peptide therapeutics market will see a considerable growth of 5.0% during the forecast period. The burden of cancer is growing at an alarming pace across the country. According to the Centers for Disease Control and Prevention (CDC), by end of 2020, the number of new cancer cases is expected increase from around 24% in men to more than one million cases every year in the US, and by about 21% in women to more than 900,000 cases per year in the country. 

Most of the current FDA-approved chemo therapeutics for cancer treatment have harsh side effects due to their inability to discriminate between healthy cells and cancer cells. Hence, in recent years, an increase in efforts is being observed across the country to improve the selectivity of cancer therapeutics by targeting cancer biomarkers, such as over expressed membrane receptors.

Browse the full report description of "US Peptide Therapeutics Market Size, Share & Trends Analysis Report, By Route of Administration (Oral and Parenteral), by Application (Cancer, Metabolic Disorder, Gastrointestinal Disorders, Central Nervous System Disorders, Respiratory Disorders, and Others), Forecast 2020-2026" at https://www.omrglobal.com/industry-reports/us-peptide-therapeutics-market

Various companies across the country are developing new novel therapies. For instance, in August 2020, Sapience Therapeutics, Inc. announced dose administration for the first patient in a Phase 1/2, open-label, dose-escalation, and expansion study of single-agent ST101. The company is focused on the R&D of peptide therapeutics to address difficult-to-treat oncology indications. ST101 is a peptide therapy that is being evaluated by the company for the treatment of adults with unresectable and metastatic solid tumors that are not eligible for other therapies or have progressed on prior therapies.

Market Coverage

Key questions addressed by the report

• What is the market growth rate during the forecast period?
• Which segment/region dominates the market in the base year?
• Which segment/region will project the fastest growth in the market during the forecast period?
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

US Peptide Therapeutics Market – Segmentation

By Route of Administration

• Oral
• Parenteral

By Application

• Cancer
• Metabolic Disorder
• Gastrointestinal Disorders
• Central Nervous System Disorders
• Respiratory Disorders
• Others (Kidney Disorder and Autoimmune Disorder)